A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Public ClinicalTrials.gov record NCT00373529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients With Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This study will evaluate the efficacy of clofarabine in elderly patients with acute myelogenous leukemia (AML) who are unlikely to benefit from treatment with intensive chemotherapy regimens (cytarabine and anthracycline based regimens) used in younger patients with AML.
Study identification
- NCT ID
- NCT00373529
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 116 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2006
- Primary completion
- Apr 30, 2008
- Completion
- Apr 30, 2010
- Last update posted
- Apr 13, 2014
2006 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinical Hospital | Phoenix | Arizona | — | — |
| Arizona Cancer Center | Tucson | Arizona | — | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | — | — |
| Scripps Cancer Center | San Diego | California | — | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | — | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | — | — |
| Emory University School of Medicine | Atlanta | Georgia | — | — |
| Medical College of Georgia | Augusta | Georgia | — | — |
| Rush University Medical Center | Chicago | Illinois | — | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | — | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | — | — |
| Mount Sinai School of Medicine | New York | New York | — | — |
| Oregon Health and Science University | Portland | Oregon | — | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | — | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | — | — |
| University of MD Anderson Cancer Center | Houston | Texas | — | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | — | — |
| University of Utah - Huntsman Cancer Institute | Salt Lake City | Utah | — | — |
| Seattle Cancer Care Alliance | Seattle | Washington | — | — |
| West Virginia University - HSC | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00373529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2014 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00373529 live on ClinicalTrials.gov.